|
IL36670A
(en)
|
1971-04-21 |
1974-09-10 |
Sela M |
Therapeutic basic copolymers of amino acids
|
|
IL113812A
(en)
|
1994-05-24 |
2000-06-29 |
Yeda Res & Dev |
Copolymer-1 pharmaceutical compositions containing it and its use
|
|
US6214791B1
(en)
|
1997-01-10 |
2001-04-10 |
Yeda Research And Development Co. Ltd. |
Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
|
|
IL119989A0
(en)
|
1997-01-10 |
1997-04-15 |
Yeda Res & Dev |
Pharmaceutical compositions for oral treatment of multiple sclerosis
|
|
ES2527760T3
(es)
|
1998-07-23 |
2015-01-29 |
Yeda Research And Development Co., Ltd. |
Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
|
|
JP2003521448A
(ja)
|
1998-07-23 |
2003-07-15 |
ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ |
合成ペプチドおよび自己免疫疾患治療のための使用方法
|
|
WO2000005250A1
(en)
|
1998-07-23 |
2000-02-03 |
Yeda Research And Development Co., Ltd |
Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
|
|
US6514938B1
(en)
|
1998-09-25 |
2003-02-04 |
Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
US6800287B2
(en)
|
1998-09-25 |
2004-10-05 |
Yeda Research And Development Co., Ltd. |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
SI1115743T1
(sl)
|
1998-09-25 |
2010-01-29 |
Yeda Res And Dev Co Ltd The We |
Polipeptidi, sorodni kopolimeru 1, za uporabo kot markerji molekulske mase in za terapevtsko uporabo
|
|
AU6281599A
(en)
|
1998-10-02 |
2000-04-26 |
Yeda Research And Development Co. Ltd. |
Alternate day administration of copolymer 1 for treating autoimmune diseases
|
|
CA2355400A1
(en)
|
1998-11-12 |
2000-05-18 |
Yeda Research And Development Co., Ltd. |
Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd
|
|
PT1248643E
(pt)
|
2000-01-20 |
2005-10-31 |
Yeda Res & Dev |
Utilizacao de copolimero 1 e peptidos e polipeptidos congeneres e de celulas t tratadas co estes compostos para terapia neuroprotectora
|
|
WO2001060392A1
(en)
|
2000-02-18 |
2001-08-23 |
Yeda Research And Development Co., Ltd. At The Weizmann Institute Of Science |
Oral, nasal and pulmonary dosage formualtions of copolymer 1
|
|
US7022663B2
(en)
|
2000-02-18 |
2006-04-04 |
Yeda Research And Development Co., Ltd. |
Oral, nasal and pulmonary dosage formulations of copolymer 1
|
|
US20020077278A1
(en)
|
2000-06-05 |
2002-06-20 |
Yong V. Wee |
Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
|
CA2411536A1
(en)
|
2000-06-05 |
2001-12-13 |
V. Wee Yong |
The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
|
DK1294390T3
(da)
|
2000-06-07 |
2006-04-03 |
Yeda Res & Dev |
Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celelr behandlet dermed til neurobeskyttelse mod glutamattoksicitet
|
|
WO2002076503A1
(en)
|
2000-06-20 |
2002-10-03 |
Mayo Foundation For Medical Education And Research |
Treatment of central nervous system diseases by antibodies against glatiramer acetate
|
|
SI1459065T1
(sl)
|
2001-12-04 |
2010-11-30 |
Teva Pharma |
Postopki za merjenje potentnosti glatiramer acetata
|
|
IL160105A0
(en)
|
2001-12-06 |
2004-06-20 |
Yeda Res & Dev |
Vaccine for treatment of motor neurone diseases
|
|
US7507531B2
(en)
|
2002-10-17 |
2009-03-24 |
Decode Genetics Chf. |
Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
|
|
US20060019269A1
(en)
|
2002-10-17 |
2006-01-26 |
Decode Genetics, Inc. |
Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
|
|
US20080293750A1
(en)
|
2002-10-17 |
2008-11-27 |
Anna Helgadottir |
Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
|
|
US7851486B2
(en)
|
2002-10-17 |
2010-12-14 |
Decode Genetics Ehf. |
Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
|
|
WO2004043995A2
(en)
|
2002-11-13 |
2004-05-27 |
Apotex Pharmachem Inc. |
Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
|
|
CN102580069B
(zh)
|
2003-01-07 |
2015-09-30 |
耶达研究及发展有限公司 |
用于治疗性免疫接种的含共聚物1的滴眼用疫苗
|
|
NZ569331A
(en)
|
2003-01-21 |
2010-08-27 |
Yeda Res & Dev |
COP 1 for treatment of inflammatory bowel diseases
|
|
EP1603530A1
(en)
|
2003-03-04 |
2005-12-14 |
Teva Pharmaceutical Industries Limited |
Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
|
|
PT1638589E
(pt)
|
2003-05-14 |
2014-06-12 |
Teva Pharma |
Terapia combinada com acetato de glatirâmero e mitoxantrona para o tratamento da esclerose múltipla
|
|
US20050064483A1
(en)
*
|
2003-08-28 |
2005-03-24 |
Baylor College Of Medicine |
Gene expression profiling technology for treatment evaluation of multiple sclerosis
|
|
CA2540701A1
(en)
|
2003-09-29 |
2005-04-07 |
Chugai Seiyaku Kabushiki Kaisha |
Proteins expressed in nk cells
|
|
US20050170004A1
(en)
|
2003-10-31 |
2005-08-04 |
Vered Rosenberger |
Nanoparticles for drug delivery
|
|
CA2546077C
(en)
|
2003-11-12 |
2016-07-05 |
Yeda Research And Development Co. Ltd. |
Vaccine and method for treatment of neurodegenerative diseases
|
|
JP2007538003A
(ja)
|
2004-01-30 |
2007-12-27 |
デコード ジェネティクス イーエッチエフ． |
心筋梗塞、脳卒中および末梢動脈閉塞疾患に対する感受性遺伝子、治療の方法
|
|
US20100216863A1
(en)
|
2004-01-30 |
2010-08-26 |
Decode Genetics Ehf. |
Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
|
|
WO2005082110A2
(en)
*
|
2004-02-26 |
2005-09-09 |
Illumina Inc. |
Haplotype markers for diagnosing susceptibility to immunological conditions
|
|
AU2005218625A1
(en)
|
2004-03-03 |
2005-09-15 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and riluzole
|
|
US20050266410A1
(en)
|
2004-05-19 |
2005-12-01 |
Emily Walsh |
Methods of Human Leukocyte Antigen typing by neighboring single nucleotide polymorphism haplotypes
|
|
CA2571035A1
(en)
*
|
2004-06-25 |
2006-01-12 |
Id Biomedical Corporation Of Quebec |
Compositions and methods for treating neurological disorders
|
|
US20090048181A1
(en)
|
2004-09-02 |
2009-02-19 |
Schipper Hyman M |
Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
|
|
US7495072B2
(en)
|
2004-09-09 |
2009-02-24 |
Teva Pharmaceutical Industries, Ltd. |
Process for preparation of mixtures of polypeptides using purified hydrobromic acid
|
|
WO2006029411A2
(en)
|
2004-09-09 |
2006-03-16 |
Yeda Research And Development Co. Ltd. |
Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
|
|
AU2005302500B2
(en)
|
2004-10-29 |
2008-11-27 |
Sandoz Ag |
Processes for preparing glatiramer
|
|
KR20070108388A
(ko)
|
2005-02-02 |
2007-11-09 |
테바 파마슈티컬 인더스트리즈 리미티드 |
가수소분해를 이용한 폴리펩타이드의 혼합물의 제조방법
|
|
US20100167983A1
(en)
|
2007-10-22 |
2010-07-01 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
|
|
PL1848415T3
(pl)
|
2005-02-17 |
2013-10-31 |
Teva Pharma |
Terapia kombinowana obejmująca octan glatirameru oraz rasagilinę do leczenia stwardnienia rozsianego
|
|
WO2006116602A2
(en)
|
2005-04-25 |
2006-11-02 |
Yeda Research And Development Company |
Markers associated with the therapeutic efficacy of glatiramer acetate
|
|
WO2007030573A2
(en)
|
2005-09-09 |
2007-03-15 |
Yeda Research And Development Co. Ltd. |
Polypeptides useful for molecular weight determinations
|
|
WO2007081975A2
(en)
|
2006-01-11 |
2007-07-19 |
Teva Pharmaceutical Industries, Ltd. |
Method of treating multiple sclerosis
|
|
US20080118553A1
(en)
|
2006-06-12 |
2008-05-22 |
Anton Frenkel |
Tannate salt form of polypeptide mixtures, their preparation and use
|
|
WO2008006026A1
(en)
|
2006-07-05 |
2008-01-10 |
Momenta Pharmaceuticals, Inc. |
Improved process for the preparation of copolymer-1
|
|
US20080131887A1
(en)
*
|
2006-11-30 |
2008-06-05 |
Stephan Dietrich A |
Genetic Analysis Systems and Methods
|
|
US7795033B2
(en)
|
2007-03-19 |
2010-09-14 |
The United States Of America As Represented By The Department Of Health And Human Services |
Methods to predict the outcome of treatment with antidepressant medication
|
|
US20090149541A1
(en)
|
2007-11-28 |
2009-06-11 |
Yafit Stark |
Method of delaying the onset of clinically definite multiple sclerosis
|
|
US20090177487A1
(en)
|
2008-01-07 |
2009-07-09 |
Tera Eerkes |
Methods for Assessing Genetic Compatibility
|
|
US20110158979A1
(en)
|
2008-06-13 |
2011-06-30 |
Prognomix, Inc. |
Genetic component of complications in type 2 diabetes
|
|
US20100003691A1
(en)
|
2008-07-04 |
2010-01-07 |
Axial Biotech, Inc. |
Genetic Markers Associated with Degenerative Disc Disease and Uses Thereof
|
|
EP2406396A2
(en)
*
|
2009-03-12 |
2012-01-18 |
Brainco Biopharma, S.L. |
A genotyping tool for improving the prognostic and clinical management of ms patients
|
|
US20120073585A1
(en)
|
2009-04-08 |
2012-03-29 |
Cedars-Sinai Medical Center |
Methods of predicting complication and surgery in crohn's disease
|
|
RS52367B
(sr)
|
2009-07-15 |
2012-12-31 |
Teva Pharmaceutical Industries Ltd. |
Formulacije glatiramer acetata smanjene zapremine i postupci primene
|
|
US8920373B2
(en)
|
2009-07-15 |
2014-12-30 |
Teva Pharmaceutical Industries, Ltd. |
Reduced volume formulation of glatiramer acetate and methods of administration
|
|
ES2612001T4
(es)
|
2009-08-20 |
2018-02-07 |
Yeda Research & Development Company, Ltd. |
Terapia de baja frecuencia con acetato de glatirámero
|
|
US8853378B2
(en)
|
2009-10-09 |
2014-10-07 |
Georgetown University |
Polynucleotides that home to atherosclerotic plaque
|
|
US8759302B2
(en)
*
|
2010-03-16 |
2014-06-24 |
Teva Pharmaceutical Industries, Ltd. |
Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
|
|
NZ703122A
(en)
|
2010-10-11 |
2016-06-24 |
Teva Pharma |
Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
|
|
KR20140101730A
(ko)
|
2011-10-10 |
2014-08-20 |
테바 파마슈티컬 인더스트리즈 리미티드 |
글라티라머 아세테이트에 대한 임상 반응을 예측하는 데 유용한 단일 뉴클레오티드 다형성
|
|
MX2015004563A
(es)
|
2012-10-10 |
2015-07-14 |
Teva Pharma |
Biomarcadores predictivos para respuesta clinica para acetato de glatiramero.
|
|
JP2016503803A
(ja)
|
2012-12-21 |
2016-02-08 |
テバ ファーマシューティカル インダストリーズ リミティド |
酢酸グラチラマーの経粘膜送達
|
|
CA2895457A1
(en)
|
2012-12-21 |
2014-06-26 |
Teva Pharmaceutical Industries Ltd. |
Oral transmucosal delivery of glatiramer acetate
|
|
JP2016504039A
(ja)
|
2013-01-04 |
2016-02-12 |
テバ ファーマシューティカル インダストリーズ リミティド |
グラチラマーアセテート関連医薬品の特性決定
|
|
MX2015012156A
(es)
|
2013-03-12 |
2015-11-30 |
Teva Pharma |
Terapia de induccion de rituximab seguida por terapia de acetato de glatiramer.
|
|
UY35790A
(es)
|
2013-10-21 |
2015-05-29 |
Teva Pharma |
Marcadores genéticos que predicen la respuesta al acetato de glatiramer
|
|
US9155775B1
(en)
|
2015-01-28 |
2015-10-13 |
Teva Pharmaceutical Industries, Ltd. |
Process for manufacturing glatiramer acetate product
|